ES2233938T3 - Chaperonina 10. - Google Patents

Chaperonina 10.

Info

Publication number
ES2233938T3
ES2233938T3 ES95902003T ES95902003T ES2233938T3 ES 2233938 T3 ES2233938 T3 ES 2233938T3 ES 95902003 T ES95902003 T ES 95902003T ES 95902003 T ES95902003 T ES 95902003T ES 2233938 T3 ES2233938 T3 ES 2233938T3
Authority
ES
Spain
Prior art keywords
baselineskip
cpn10
epf
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902003T
Other languages
English (en)
Spanish (es)
Inventor
Halle Morton
Alice Christina Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Application granted granted Critical
Publication of ES2233938T3 publication Critical patent/ES2233938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
ES95902003T 1993-11-30 1994-11-30 Chaperonina 10. Expired - Lifetime ES2233938T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM270593 1993-11-30
AUPM823494 1994-09-16
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10

Publications (1)

Publication Number Publication Date
ES2233938T3 true ES2233938T3 (es) 2005-06-16

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902003T Expired - Lifetime ES2233938T3 (es) 1993-11-30 1994-11-30 Chaperonina 10.

Country Status (11)

Country Link
US (3) US6113899A (https=)
EP (2) EP0733071A4 (https=)
JP (3) JP3545408B2 (https=)
AT (1) ATE282634T1 (https=)
AU (2) AU684578B2 (https=)
CA (1) CA2177179C (https=)
DE (1) DE69434137T2 (https=)
ES (1) ES2233938T3 (https=)
NZ (2) NZ276670A (https=)
PT (1) PT731811E (https=)
WO (2) WO1995015339A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
JP2001509396A (ja) * 1997-07-10 2001-07-24 メディカル リサーチ カウンシル シャペロン断片
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
CN100406891C (zh) * 2001-06-27 2008-07-30 詹森药业有限公司 利用EPF受体鉴定结合或调节hDRR活性的化合物以及hDRR的分离
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US20070275890A1 (en) * 2004-01-16 2007-11-29 Johnson Barbara J Chaperonin 10 Modulation Of Toll-Like Receptor-Inducible Cytokine And Chemokine Secretion
CN101309934B (zh) 2005-08-31 2014-02-12 悉生物有限公司 修饰的伴侣蛋白10
JP2009511610A (ja) * 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
MX2012004067A (es) * 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192634B (en) * 1985-03-12 1990-03-21 Univ Queensland Method of detecting early pregnancy factor (epf) in mammals, purifying epf and method for providing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland METHOD FOR TREATING MAMMALS WITH ANTIBODIES AGAINST THE EARLY RECEPTION FACTOR (EPF).
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10

Also Published As

Publication number Publication date
JP3986481B2 (ja) 2007-10-03
AU1103495A (en) 1995-06-19
US7358329B2 (en) 2008-04-15
JP3545408B2 (ja) 2004-07-21
CA2177179A1 (en) 1995-06-08
ATE282634T1 (de) 2004-12-15
EP0731811B1 (en) 2004-11-17
WO1995015339A1 (en) 1995-06-08
EP0733071A4 (en) 1997-02-26
AU684578B2 (en) 1997-12-18
AU684577B2 (en) 1997-12-18
CA2177179C (en) 2006-10-17
AU1103695A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
EP0731811A1 (en) 1996-09-18
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
NZ276670A (en) 1998-01-26
WO1995015338A1 (en) 1995-06-08
PT731811E (pt) 2005-04-29
NZ276672A (en) 1998-01-26
US6417334B1 (en) 2002-07-09
US6113899A (en) 2000-09-05
JP2004067698A (ja) 2004-03-04
EP0731811A4 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
ES2233938T3 (es) Chaperonina 10.
ES2345746T3 (es) Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
ES2253241T3 (es) Detivados cilutrinados de la fibrina y su utilizacion para el diagnostico o el tratamiento de la poliartritis reumatoide.
Cavanagh Production in vitro of mouse early pregnancy factor and purification to homogeneity
US5859189A (en) Peptides and polypeptides derived from the submaxillary gland of the rat, corresponding polyclonal and monoclonal antibodies, corresponding hybridomas and uses of these products for diagnosis, for detection or therapeutic purposes
JPH05508847A (ja) 伝達因子および使用方法
CA2176948C (en) Chaperonin 10
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
JP2815582B2 (ja) 原発性胆汁肝硬変自己抗原
ES2300625T3 (es) Peptido paralizante de musaraña para uso en terapia neuromuscular.
ES2326324T3 (es) Me-5, me-2 y epp2: antigenos de proteina humana reactivos con anticuerpos presentes en el suero de mujeres que padecen de endometriosis.
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
Pleau et al. [19] Thymulin
WO1991015236A1 (en) Treatment of autoimmune diseases
US5785986A (en) Water channel
JPS61100598A (ja) 抗原性ペプチド化合物
AU662433B2 (en) Leukaemia inhibitory factor-binding protein
Otto et al. Production of polyclonal antibodies to feline tumor necrosis factor
Naz Cloning and Sequencing of Sperm Antigens Involved in Oocyte Interaction: Clinical applications in infertility and immunocontraception
Naz applications in infertility and immunocontraception